London, UK – This year, Veritas Genetics had the opportunity to participate in the Annual Scientific Meeting of the British Gynaecological Cancer Society (BGCS), held from July 9 to 11, 2025, in London. This esteemed gathering, a pivotal event for multidisciplinary professionals in gynaecological oncology, centers this year on the crucial theme of “Improving Precision in Cancer Care and Prevention.”

The BGCS Annual Scientific Meeting is renowned as the foremost scientific meeting of its kind, uniting leading experts, clinicians, researchers, and allied professionals involved in the screening, prevention, diagnosis, and treatment of gynaecological cancers. The diverse program covers all facets of gynaecological oncology, including dedicated sessions for pathologists, surgical oncologists, clinical nurse specialists, and unit leads.

Veritas’ presence at this significant conference highlights the profound value our advanced genomic services and products bring to the evolving landscape of gynaecological cancer. Our innovative solutions are instrumental in achieving greater precision in patient management and preventative strategies within this critical field, offering crucial support for:

• Early detection and risk stratification – Utilizing advanced genomic screening to identify individuals at elevated genetic risk for various gynaecological cancers, enabling proactive surveillance and personalized prevention plans.
• Personalized treatment pathways – Providing in-depth genomic insights that can inform more targeted and effective therapeutic decisions, moving towards truly individualized cancer care.
• Monitoring and recurrence management – Offering tools that can aid in tracking disease progression and detecting minimal residual disease, which is vital for managing recurrence.
• Population health initiatives – Contributing to broader efforts in understanding the genetic underpinnings of gynaecological cancers within populations, leading to more effective public health interventions and screening programs.

Veritas’s participation at the BGCS Annual Scientific Meeting underscores our unwavering dedication to leveraging the power of genomics to transform outcomes for patients facing gynaecological cancers and to contribute significantly to the global efforts in cancer prevention.